Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Reata Pharmaceuticals

12 Health Care Stocks Moving In Friday's Intraday Session

Reata Pharmaceuticals Earnings Perspective: Return On Capital Employed

Reata Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Reata Pharmaceuticals's (NASDAQ:RETA) reported sales totaled $914.00 thousand. Despite a 13.52% increase in earnings, the company posted a loss of $73.84 million.

Where Reata Pharmaceuticals Stands With Analysts

Where Reata Pharmaceuticals Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pharma Stock Shoots Up As FDA Accepts NDA For Neuromuscular Disorder Drug Under Priority Review

Reata Pharmaceuticals (NASDAQ: RETA) announced that the U.S. Food and Drug Administration has accepted New Drug Application (NDA) for its lead drug candidate omaveloxolone for the treatment of patients with Friedreich's ataxia.

Recap: Reata Pharmaceuticals Q1 Earnings

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Reata Pharmaceuticals Earnings Preview

Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Reata Pharmaceuticals will report an earnings per share (EPS) of $-2.15.

12 Health Care Stocks Moving In Monday's Intraday Session

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022

Reata Pharmaceuticals's Return on Invested Capital Insights

Reata Pharmaceuticals's Return on Invested Capital Insights

Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q4 sales of $934.00 thousand. Earnings fell to a loss of $85.39 million, resulting in a 18.84% decrease from last quarter.

1

Organisations

B of A Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play